SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3414-3418

  Yang, Su Hui ^a   Song, Chin Hee ^a   Van, Hue Thi My ^a   Park, Eunsook ^a   Khadka, Daulat Bikram ^a   Gong, Eun Yeung ^a   Lee, Keesook ^a   Cho, Won Jea ^a  

^a Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ISOQUINOLINE; NICOTINAMIDE DERIVATIVE;

ADVANCED CANCER; ANTIANDROGEN THERAPY; ARTICLE; BINDING AFFINITY; CANCER HORMONE THERAPY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; ISOQUINOLINES; MALE; NIACINAMIDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876869320     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3014103     Document Type: Article

References (26)

1. Scher, H. I.; Steineck, G.; Kelly, W. K. Hormone-refractory (D3) prostate cancer: refining the concept Urology 1995, 46, 142-148
2. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinanen, R.; Palmberg, C.; Palotie, A.; Tammela, T.; Isola, J.; Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nature Genet. 1995, 9, 401-406
3. Edwards, J.; Krishna, N. S.; Grigor, K. M.; Bartlett, J. M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br. J. Cancer 2003, 89, 552-556
4. Taplin, M. E.; Bubley, G. J.; Ko, Y. J.; Small, E. J.; Upton, M.; Rajeshkumar, B.; Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res. 1999, 59, 2511-2515
5. Hara, T.; Miyazaki, J.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res. 2003, 63, 149-153
6. Weber, M. J.; Gioeli, D. Ras signaling in prostate cancer progression J. Cell Biochem. 2004, 91, 13-25
7. Gregory, C. W.; He, B.; Johnson, R. T.; Ford, O. H.; Mohler, J. L.; French, F. S.; Wilson, E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res. 2001, 61, 4315-4319
8. Schellhammer, P. F.; Venner, P.; Haas, G. P.; Small, E. J.; Nieh, P. T.; Seabaugh, D. R.; Patterson, A. L.; Klein, E.; Wajsman, Z.; Furr, B.; Chen, Y.; Kolvenbag, G. J. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade J. Urol. 1997, 157, 1731-1735
9. Schurko, B.; Oh, W. K. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer Nature Clin. Pract. Oncol. 2008, 5, 506-507
10. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor Nature 1997, 389, 753-758
11. Matias, P. M.; Donner, P.; Coelho, R.; Thomaz, M.; Peixoto, C.; Macedo, S.; Otto, N.; Joschko, S.; Scholz, P.; Wegg, A.; Basler, S.; Schafer, M.; Egner, U.; Carrondo, M. A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations J. Biol. Chem. 2000, 275, 26164-26171
12. Moras, D.; Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function Curr. Opin. Cell Biol. 1998, 10, 384-391
13. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 6201-6206
14. Kinoyama, I.; Taniguchi, N.; Toyoshima, A.; Nozawa, E.; Kamikubo, T.; Imamura, M.; Matsuhisa, A.; Samizu, K.; Kawanimani, E.; Niimi, T.; Hamada, N.; Koutoku, H.; Furutani, T.; Kudoh, M.; Okada, M.; Ohta, M.; Tsukamoto, S. (+)-(2 R,5 S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl- N -[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist J. Med. Chem. 2006, 49, 716-726
15. Goto, T.; Ohta, K.; Fujii, S.; Ohta, S.; Endo, Y. Design and synthesis of androgen receptor full antagonists bearing a p -carborane cage: promising ligands for anti-androgen withdrawal syndrome J. Med. Chem. 2010, 53, 4917-4926
16. Jung, M. E.; Ouk, S.; Yoo, D.; Sawyers, C. L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 2010, 53, 2779-2796
17. Song, C. H.; Yang, S. H.; Park, E.; Cho, S. H.; Gong, E. Y.; Khadka, D. B.; Cho, W. J.; Lee, K. Structure-based virtual screening and identification of a novel androgen receptor antagonist J. Biol. Chem. 2012, 287, 30769-30780
18. Ladziata, U.; Koposov, A. Y.; Lo, K. Y.; Willging, J.; Nemykin, V. N.; Zhdankin, V. V. Synthesis, structure, and chemoselective reactivity of N -(2-iodylphenyl)acylamides: hypervalent iodine reagents bearing a pseudo-six-membered ring scaffold Angew. Chem., Int. Ed. Engl. 2005, 44, 7127-7131
19. Cantin, L.; Faucher, F.; Couture, J. F.; de Jesus-Tran, K. P.; Legrand, P.; Ciobanu, L. C.; Frechette, Y.; Labrecque, R.; Singh, S. M.; Labrie, F.; Breton, R. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12 J. Biol. Chem. 2007, 282, 30910-30919
20. Zhong, H. M.; Villani, F. J.; Marzouq, R. Improved and practical synthesis of 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride Org. Process Res. Dev. 2007, 11, 463-465
21. Sall, D. J.; Grunewald, G. L. Inhibition of phenylethanolamine N -methyltransferase (PNMT) by aromatic hydroxy-substituted 1,2,3,4,- tetrahydroisoquinolines: further studies on the hydrophilic pocket of the aromatic ring binding region of the active site J. Med. Chem. 1987, 30, 2208-2216
22. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor J. Biol. Chem. 2005, 280, 37747-37754
23. Attardi, B.; Ono, S. Cytosol androgen receptor from kidney of normal and testicular feminized (Tfm) mice Cell 1974, 2, 205-212
24. Lee, S. J.; Zhang, Y.; Lee, S. D.; Jung, C.; Li, X.; Kim, H. S.; Bae, K. H.; Jeng, M. H.; Kao, C.; Gardner, T. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer Mol. Ther. 2004, 10, 1051-1058
25. Ai, J.; Wang, Y.; Dar, J. A.; Liu, J.; Liu, L.; Nelson, J. B.; Wang, Z. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Mol. Endocrinol. 2009, 23, 1963-1972
26. Heinlein, C. A.; Chang, C. Androgen receptor (AR) coregulators: an overview Endocr. Rev. 2002, 23, 175-200